1
|
Faricier R, Keltz RR, Hartley T, McKelvie RS, Suskin NG, Prior PL, Keir DA. Quantifying Improvement in V˙ o2peak and Exercise Thresholds in Cardiovascular Disease Using Reliable Change Indices. J Cardiopulm Rehabil Prev 2024; 44:121-130. [PMID: 38064643 DOI: 10.1097/hcr.0000000000000837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/27/2024]
Abstract
PURPOSE Improving aerobic fitness through exercise training is recommended for the treatment of cardiovascular disease (CVD). However, strong justifications for the criteria of assessing improvement in key parameters of aerobic function including estimated lactate threshold (θ LT ), respiratory compensation point (RCP), and peak oxygen uptake (V˙ o2peak ) at the individual level are not established. We applied reliable change index (RCI) statistics to determine minimal meaningful change (MMC RCI ) cutoffs of θ LT , RCP, and V˙ o2peak for individual patients with CVD. METHODS Sixty-six stable patients post-cardiac event performed three exhaustive treadmill-based incremental exercise tests (modified Bruce) ∼1 wk apart (T1-T3). Breath-by-breath gas exchange and ventilatory variables were measured by metabolic cart and used to identify θ LT , RCP, and V˙ o2peak . Using test-retest reliability and mean difference scores to estimate error and test practice/exposure, respectively, MMC RCI values were calculated for V˙ o2 (mL·min -1. kg -1 ) at θ LT , RCP, and V˙ o2peak . RESULTS There were no significant between-trial differences in V˙ o2 at θ LT ( P = .78), RCP ( P = .08), or V˙ o2peak ( P = .74) and each variable exhibited excellent test-retest variability (intraclass correlation: 0.97, 0.98, and 0.99; coefficient of variation: 6.5, 5.4, and 4.9% for θ LT , RCP, and V˙ o2peak , respectively). Derived from comparing T1-T2, T1-T3, and T2-T3, the MMC RCI for θ LT were 3.91, 3.56, and 2.64 mL·min -1. kg -1 ; 4.01, 2.80, and 2.79 mL·min -1. kg -1 for RCP; and 3.61, 3.83, and 2.81 mL·min -1. kg -1 for V˙ o2peak . For each variable, MMC RCI scores were lowest for T2-T3 comparisons. CONCLUSION These MMC RCI scores may be used to establish cutoff criteria for determining meaningful changes for interventions designed to improve aerobic function in individuals with CVD.
Collapse
Affiliation(s)
- Robin Faricier
- School of Kinesiology, University of Western Ontario, London, Ontario, Canada (Mr Faricier, Ms Keltz, and Dr Keir); Lawson Health Research Institute, London, Ontario, Canada (Messrs Faricier and Hartley, Ms Keltz, and Drs Suskin, Prior, and Keir); Cardiac Rehabilitation and Secondary Prevention Program, St Joseph's Health Care, London, Ontario, Canada (Mr Hartley and Drs McKelvie, Suskin, and Prior); Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada (Drs McKelvie and Suskin); and Toronto General Hospital Research Institute, Toronto, Ontario, Canada (Dr Keir)
| | | | | | | | | | | | | |
Collapse
|
2
|
Fudim M, Boortz-Marx RL, Ganesh A, DeVore AD, Patel CB, Rogers JG, Coburn A, Johnson I, Paul A, Coyne BJ, Rao SV, Gutierrez JA, Kiefer TL, Kong DF, Green CL, Jones WS, Felker GM, Hernandez AF, Patel MR. Splanchnic Nerve Block for Chronic Heart Failure. JACC-HEART FAILURE 2020; 8:742-752. [DOI: 10.1016/j.jchf.2020.04.010] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 04/01/2020] [Accepted: 04/01/2020] [Indexed: 11/29/2022]
|
3
|
Lim FY, Yap J, Gao F, Teo LL, Lam CS, Yeo KK. Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. Int J Cardiol 2018; 263:88-93. [DOI: 10.1016/j.ijcard.2018.04.021] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 03/09/2018] [Accepted: 04/05/2018] [Indexed: 02/07/2023]
|
4
|
Nichols S, Gleadall-Siddall DO, Antony R, Clark AL, Cleland JGF, Carroll S, Ingle L. Estimated peak functional capacity: an accurate method for assessing change in peak oxygen consumption after cardiac rehabilitation? Clin Physiol Funct Imaging 2017; 38:681-688. [PMID: 28857391 DOI: 10.1111/cpf.12468] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 07/14/2017] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Cardiopulmonary exercise testing (CPET) is the 'gold standard' method of determining VO2peak . When CPET is unavailable, VO2peak may be estimated from treadmill or cycle ergometer workloads and expressed as estimated metabolic equivalents (METs). Cardiac rehabilitation (CR) programmes use estimated VO2peak (METs) to report changes in cardiorespiratory fitness (CRF). However, the accuracy of determining changes in VO2peak based on estimated functional capacity is not known. METHODS A total of 27 patients with coronary heart disease (88·9% male; age 59·5 ± 10·0 years, body mass index 29·6 ± 3·8 kg m-2 ) performed maximal CPET before and after an exercise-based CR intervention. VO2peak was directly determined using ventilatory gas exchange data and was also estimated using the American College of Sports Medicine (ACSM) leg cycling equation. Agreement between changes in directly determined VO2peak and estimated VO2peak was evaluated using Bland-Altman limits of agreement (LoA) and intraclass correlation coefficients. RESULTS Directly determined VO2peak did not increase following CR (0·5 ml kg-1 min-1 (2·7%); P = 0·332). Estimated VO2peak increased significantly (0·4 METs; 1·4 ml kg-1 min-1 ; 6·7%; P = 0·006). The mean bias for estimated VO2peak versus directly determined VO2peak was 0·7 ml kg-1 min-1 (LoA -4·7 to 5·9 ml kg-1 min-1 ). Aerobic efficiency (ΔVO2 /ΔWR slope) was significantly associated with estimated VO2peak measurement error. CONCLUSION Change in estimated VO2peak derived from the ACSM leg cycling equation is not an accurate surrogate for directly determined changes in VO2peak . Our findings show poor agreement between estimates of VO2peak and directly determined VO2peak . Applying estimates of VO2peak to determine CRF change may over-estimate the efficacy of CR and lead to a different interpretation of study findings.
Collapse
Affiliation(s)
- S Nichols
- Faculty of Medical Sciences, Sport and Exercise Science, School of Biomedical Science, Newcastle University, Newcastle upon Tyne, UK
| | - D O Gleadall-Siddall
- Sport Health and Exercise Science, University of Hull, Cottingham Road, Hull, HU6 7RX, Cottingham, UK
| | - R Antony
- Academic Cardiology, Castle Hill Hospital, Cottingham, UK
| | - A L Clark
- Academic Cardiology, Castle Hill Hospital, Cottingham, UK
| | - J G F Cleland
- Faculty of Medicine, Imperial College London, National Heart and Lung Institute, London, UK
| | - S Carroll
- Sport Health and Exercise Science, University of Hull, Cottingham Road, Hull, HU6 7RX, Cottingham, UK
| | - L Ingle
- Sport Health and Exercise Science, University of Hull, Cottingham Road, Hull, HU6 7RX, Cottingham, UK
| |
Collapse
|
5
|
Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, Dixon DL, Abouzaki N, Oddi-Erdle C, Biondi-Zoccai G, Arena R, Abbate A. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol 2017; 40:626-632. [PMID: 28475816 DOI: 10.1002/clc.22719] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 03/15/2017] [Accepted: 03/21/2017] [Indexed: 02/05/2023] Open
Abstract
Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of confirmed HF cases in the United States. However, there are no highly effective evidence-based treatments currently available for these patients. Inflammation correlates positively with adverse outcomes in HF patients. Interleukin (IL)-1, a prototypical inflammatory cytokine, has been implicated as a driver of diastolic dysfunction in preclinical animal models and a pilot clinical trial. The Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) is a phase 2, 2:1 randomized, double-blind, placebo-controlled clinical trial that will test the hypothesis that IL-1 blockade with anakinra (recombinant human IL-1 receptor antagonist) improves (1) cardiorespiratory fitness, (2) objective evidence of diastolic dysfunction, and (3) elevated inflammation in patients with HFpEF (http://www.ClinicalTrials.gov NCT02173548). The co-primary endpoints will be placebo-corrected interval changes in peak oxygen consumption and ventilatory efficiency at week 12. In addition, secondary and exploratory analyses will investigate the effects of IL-1 blockade on cardiac structure and function, systemic inflammation, endothelial function, quality of life, body composition, nutritional status, and clinical outcomes. The D-HART2 clinical trial will add to the growing body of evidence on the role of inflammation in cardiovascular disease, specifically focusing on patients with HFpEF.
Collapse
Affiliation(s)
- Benjamin W Van Tassell
- Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond.,VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Leo F Buckley
- Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond.,VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Salvatore Carbone
- VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond.,Department of Experimental Medicine, Sapienza University of Rome, Italy
| | - Cory R Trankle
- VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Justin M Canada
- VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Dave L Dixon
- Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond.,VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Nayef Abouzaki
- VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Claudia Oddi-Erdle
- VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| | - Giuseppe Biondi-Zoccai
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, and Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy
| | - Ross Arena
- Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago
| | - Antonio Abbate
- VCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.,VCU Pauley Heart Center, Virginia Commonwealth University, Richmond
| |
Collapse
|
6
|
Zamani P, Tan V, Soto-Calderon H, Beraun M, Brandimarto JA, Trieu L, Varakantam S, Doulias PT, Townsend RR, Chittams J, Margulies KB, Cappola TP, Poole DC, Ischiropoulos H, Chirinos JA. Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. Circ Res 2017; 120:1151-1161. [PMID: 27927683 PMCID: PMC5376233 DOI: 10.1161/circresaha.116.309832] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 11/11/2016] [Accepted: 12/07/2016] [Indexed: 01/31/2023]
Abstract
RATIONALE Nitrate-rich beetroot juice has been shown to improve exercise capacity in heart failure with preserved ejection fraction, but studies using pharmacological preparations of inorganic nitrate are lacking. OBJECTIVES To determine (1) the dose-response effect of potassium nitrate (KNO3) on exercise capacity; (2) the population-specific pharmacokinetic and safety profile of KNO3 in heart failure with preserved ejection fraction. METHODS AND RESULTS We randomized 12 subjects with heart failure with preserved ejection fraction to oral KNO3 (n=9) or potassium chloride (n=3). Subjects received 6 mmol twice daily during week 1, followed by 6 mmol thrice daily during week 2. Supine cycle ergometry was performed at baseline (visit 1) and after each week (visits 2 and 3). Quality of life was assessed with the Kansas City Cardiomyopathy Questionnaire. The primary efficacy outcome, peak O2-uptake, did not significantly improve (P=0.13). Exploratory outcomes included exercise duration and quality of life. Exercise duration increased significantly with KNO3 (visit 1: 9.87, 95% confidence interval [CI] 9.31-10.43 minutes; visit 2: 10.73, 95% CI 10.13-11.33 minute; visit 3: 11.61, 95% CI 11.05-12.17 minutes; P=0.002). Improvements in the Kansas City Cardiomyopathy Questionnaire total symptom (visit 1: 58.0, 95% CI 52.5-63.5; visit 2: 66.8, 95% CI 61.3-72.3; visit 3: 70.8, 95% CI 65.3-76.3; P=0.016) and functional status scores (visit 1: 62.2, 95% CI 58.5-66.0; visit 2: 68.6, 95% CI 64.9-72.3; visit 3: 71.1, 95% CI 67.3-74.8; P=0.01) were seen after KNO3. Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO3 (visit 2: 199.5, 95% CI 98.7-300.2 μmol/L; visit 3: 471.8, 95% CI 377.8-565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00-132.0 μmol/L; P<0.001). KNO3 did not lead to clinically significant hypotension or methemoglobinemia. After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9 (95% CI -28.3 to -7.6) mm Hg 3.75 hours later. Peak nitric oxide metabolites concentrations were 259.3 (95% CI 176.2-342.4) μmol/L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4-232.0) minutes. CONCLUSIONS KNO3 is potentially well tolerated and improves exercise duration and quality of life in heart failure with preserved ejection fraction. This study reinforces the efficacy of KNO3 and suggests that larger randomized trials are warranted. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT02256345.
Collapse
Affiliation(s)
- Payman Zamani
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.).
| | - Victor Tan
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Haideliza Soto-Calderon
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Melissa Beraun
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Jeffrey A Brandimarto
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Lien Trieu
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Swapna Varakantam
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Paschalis-Thomas Doulias
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Raymond R Townsend
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Jesse Chittams
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Kenneth B Margulies
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Thomas P Cappola
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - David C Poole
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Harry Ischiropoulos
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| | - Julio A Chirinos
- From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.)
| |
Collapse
|
7
|
Kervio G, Ville NS, Leclercq C, Daubert JC, Carre F. Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure patients. ACTA ACUST UNITED AC 2016; 11:171-7. [PMID: 15187823 DOI: 10.1097/01.hjr.0000119964.42813.98] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The six-minute walk test (6-MWT) is widely used to assess exercise tolerance in chronic heart failure patients (CHF). The aim of this study was to analyse cardiorespiratory parameters kinetics during the 6-MWT in CHF and in healthy subjects. METHODS A treadmill, symptom-limited exercise test and a 6-MWT were performed by 14 CHF under optimal drug treatment (CHFD), 17 CHF with cardiac resynchronization (CHFP), and 12 healthy subjects. Cardiorespiratory responses were assessed by a validated portable system. RESULTS All subjects exceeded their ventilatory threshold during the 6-MWT. Healthy subjects and CHF performed the 6-MWT around 75 and 90% of peak oxygen uptake (V'O2) respectively (P<0.001). In CHF, a steady state was observed only for walking speed and V'O2, with a slight delay in comparison with healthy subjects, for whom a steady state was also observed for carbon dioxide production and ventilation (V'E). During the 6-MWT, the V'E adaptation was due mainly to an increase in tidal volume (VT) in CHFD, whereas in CHFP, it was due to a similar increase in VT and breathing frequency (f). In these patients, the 6-MWT VT/f slope was lower than in CHFD (P<0.01). CONCLUSIONS During the 6-MWT, the V'O2 steady state is slightly delayed in CHF, which could be related partly to their higher exercise intensity. Moreover, each CHF group is characterized by a specific ventilation components response during the 6-MWT.
Collapse
Affiliation(s)
- Gaëlle Kervio
- Groupe de Recherche Cardiovasculaire, Université de Rennes, France.
| | | | | | | | | |
Collapse
|
8
|
Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Piña IL, Leifer ES, Fleg JL, Blackburn G, Fonarow GC, Chase PJ, Piner L, Vest M, O'Connor CM, Ehrman JK, Walsh MN, Ewald G, Bensimhon D, Russell SD. Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. J Am Coll Cardiol 2016; 67:780-9. [PMID: 26892413 DOI: 10.1016/j.jacc.2015.11.050] [Citation(s) in RCA: 147] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 11/23/2015] [Accepted: 11/24/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND Data from a cardiopulmonary exercise (CPX) test are used to determine prognosis in patients with chronic heart failure (HF). However, few published studies have simultaneously compared the relative prognostic strength of multiple CPX variables. OBJECTIVES The study sought to describe the strength of the association among variables measured during a CPX test and all-cause mortality in patients with HF with reduced ejection fraction (HFrEF), including the influence of sex and patient effort, as measured by respiratory exchange ratio (RER). METHODS Among patients (n = 2,100, 29% women) enrolled in the HF-ACTION (HF-A Controlled Trial Investigating Outcomes of exercise traiNing) trial, 10 CPX test variables measured at baseline (e.g., peak oxygen uptake [Vo2], exercise duration, percent predicted peak Vo2 [%ppVo2], ventilatory efficiency) were examined. RESULTS Over a median follow-up of 32 months, there were 357 deaths. All CPX variables, except RER, were related to all-cause mortality (all p < 0.0001). Both %ppVo2 and exercise duration were equally able to predict (Wald chi-square: ∼141) and discriminate (c-index: 0.69) mortality. Peak Vo2 (ml·kg(-1)·min(-1)) was the strongest predictor of mortality among men (Wald chi-square: 129) and exercise duration among women (Wald chi-square: 41). Multivariable analyses showed that %ppVo2, exercise duration, and peak Vo2 (ml·kg(-1)·min(-1)) were similarly able to predict and discriminate mortality. In men, a 10% 1-year mortality rate corresponded to a peak Vo2 of 10.9 ml·kg(-1)·min(-1) versus 5.3 ml·kg(-1)·min(-1) in women. CONCLUSIONS Peak Vo2, exercise duration, and % ppVo2 carried the strongest ability to predict and discriminate the likelihood of death in patients with HFrEF. The prognosis associated with a given peak Vo2 differed by sex. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).
Collapse
Affiliation(s)
- Steven J Keteyian
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan.
| | - Mahesh Patel
- Division of Cardiology, Duke University School of Medicine, Durham, North Carolina
| | - William E Kraus
- Division of Cardiology, Duke University School of Medicine, Durham, North Carolina
| | - Clinton A Brawner
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan
| | - Timothy R McConnell
- Department of Exercise Science, Bloomsburg University, Bloomsburg, Pennsylvania
| | - Ileana L Piña
- Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York
| | - Eric S Leifer
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | - Jerome L Fleg
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | - Gordon Blackburn
- Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
| | - Gregg C Fonarow
- Ahmanson-UCLA Cardiomyopathy Center, Ronald Regan-UCLA Medical Center, Los Angeles, California
| | - Paul J Chase
- Division of Cardiology, Cone Health, Greensboro, North Carolina
| | - Lucy Piner
- Division of Cardiology, Duke University School of Medicine, Durham, North Carolina
| | - Marianne Vest
- University Hospitals Case Medical Center, Cleveland, Ohio
| | | | - Jonathan K Ehrman
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan
| | - Mary N Walsh
- St. Vincent Heart Center of Indiana, Indianapolis, Indiana
| | - Gregory Ewald
- Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri
| | - Dan Bensimhon
- Division of Cardiology, Cone Health, Greensboro, North Carolina
| | - Stuart D Russell
- Division of Cardiology, Johns Hopkins Hospital, Baltimore, Maryland
| |
Collapse
|
9
|
Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. JACC-HEART FAILURE 2016; 4:559-566. [PMID: 27039125 DOI: 10.1016/j.jchf.2016.01.008] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Revised: 01/04/2016] [Accepted: 01/20/2016] [Indexed: 12/28/2022]
Abstract
OBJECTIVES This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure. BACKGROUND Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes. METHODS We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE. RESULTS Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated. CONCLUSIONS Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).
Collapse
Affiliation(s)
- John J Lepore
- Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania.
| | - Eric Olson
- Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - Laura Demopoulos
- Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - Thomas Haws
- Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - Zixing Fang
- Quantitative Sciences, Clinical Statistics, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - April M Barbour
- Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - Michael Fossler
- Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - Victor G Davila-Roman
- Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
| | - Stuart D Russell
- Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Robert J Gropler
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
| |
Collapse
|
10
|
Barron A, Dhutia N, Mayet J, Hughes AD, Francis DP, Wensel R. Test–retest repeatability of cardiopulmonary exercise test variables in patients with cardiac or respiratory disease. Eur J Prev Cardiol 2014; 21:445-53. [DOI: 10.1177/2047487313518474] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
| | | | | | | | | | - Roland Wensel
- Imperial College, London, UK
- West Hertfordshire Hospitals NHS Trust, UK
| |
Collapse
|
11
|
Reproducibility of cardiac power output and other cardiopulmonary exercise indices in patients with chronic heart failure. Clin Sci (Lond) 2011; 122:175-81. [DOI: 10.1042/cs20110355] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Cardiac power output is a direct measure of overall cardiac function that integrates both flow- and pressure-generating capacities of the heart. The present study assessed the reproducibility of cardiac power output and other more commonly reported cardiopulmonary exercise variables in patients with chronic heart failure. Metabolic, ventilatory and non-invasive (inert gas re-breathing) central haemodynamic measurements were undertaken at rest and near-maximal exercise of the modified Bruce protocol in 19 patients with stable chronic heart failure. The same procedure was repeated 7 days later to assess reproducibility. Cardiac power output was calculated as the product of cardiac output and mean arterial pressure. Resting central haemodynamic variables demonstrate low CV (coefficient of variation) (ranging from 3.4% for cardiac output and 5.6% for heart rate). The CV for resting metabolic and ventilatory measurements ranged from 8.2% for respiratory exchange ratio and 14.2% for absolute values of oxygen consumption. The CV of anaerobic threshold, peak oxygen consumption, carbon dioxide production and respiratory exchange ratio ranged from 3.8% (for anaerobic threshold) to 6.4% (for relative peak oxygen consumption), with minute ventilation having a CV of 11.1%. Near-maximal exercise cardiac power output and cardiac output had CVs of 4.1 and 2.2%, respectively. Cardiac power output demonstrates good reproducibility suggesting that there is no need for performing more than one cardiopulmonary exercise test. As a direct measure of cardiac function (dysfunction) and an excellent prognostic marker, it is strongly advised in the assessment of patients with chronic heart failure undergoing cardiopulmonary exercise testing.
Collapse
|
12
|
Carvalho VO, Bocchi EA, Guimarães GV. Aerobic Exercise Prescription in Adult Heart Transplant Recipients: A Review. Cardiovasc Ther 2010; 29:322-6. [DOI: 10.1111/j.1755-5922.2010.00175.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
13
|
Bensimhon DR, Leifer ES, Ellis SJ, Fleg JL, Keteyian SJ, Piña IL, Kitzman DW, McKelvie RS, Kraus WE, Forman DE, Kao AJ, Whellan DJ, O'Connor CM, Russell SD. Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). Am J Cardiol 2008; 102:712-7. [PMID: 18773994 DOI: 10.1016/j.amjcard.2008.04.047] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2008] [Revised: 04/23/2008] [Accepted: 04/23/2008] [Indexed: 11/28/2022]
Abstract
Peak oxygen uptake (pVo2) is an important parameter in assessing the functional capacity and prognosis of patients with heart failure. In heart failure trials, change in pVo2 was often used to assess the effectiveness of an intervention. However, the within-subject variability of pVo2 on serial testing may limit its usefulness. This study was designed to evaluate the within-subject variability of pVo2 over 2 baseline cardiopulmonary exercise tests. As a substudy of the HF-ACTION trial, 398 subjects (73% men, 27% women; mean age 59 years) with heart failure and left ventricular ejection fraction < or =35% underwent 2 baseline cardiopulmonary exercise tests within 14 days. Mean pVo2 was unchanged from test 1 to test 2 (15.16 +/- 4.97 vs 15.18 +/- 4.97 ml/kg/min; p = 0.78). However, mean within-subject absolute change was 1.3 ml/kg/min (10th, 90th percentiles 0.1, 3.0), with 46% of subjects increasing and 48% decreasing on the second test. Other parameters, including the ventilation-to-carbon-dioxide production slope and Vo2 at ventilatory threshold, also showed significant within-subject variation with minimal mean differences between tests. In conclusion, pVo2 showed substantial within-subject variability in patients with heart failure and should be taken into account in clinical applications. However, on repeated baseline cardiopulmonary exercise tests, there appears to be no familiarization effect for Vo2 in patients with HF. Therefore, in multicenter trials, there is no need to perform >1 baseline cardiopulmonary exercise test.
Collapse
Affiliation(s)
- Daniel R Bensimhon
- Lebauer Cardiovascular Research Foundation, Greensboro, North Carolina, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Reybrouck T, Vangesselen S, Mertens L, Gewillig M. Efficiency of oxygen cost during exercise in patients with symptoms of fatigue during physical activities. Acta Paediatr 2007; 96:1311-4. [PMID: 17718784 DOI: 10.1111/j.1651-2227.2007.00416.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND With growing age, values for oxygen uptake decrease for the same level of exercise. However, some children with normal heart and normal maximal oxygen uptake complain of exertional fatigue. AIM To evaluate the energy expenditure during submaximal treadmill exercise. SUBJECTS AND METHODS In 20 children with exertional fatigue (mean age at testing: 7.9 +/- 1.8 years), oxygen uptake and respiratory gas exchange were assessed breath by breath. A graded exercise test was performed until exhaustion. Patients were compared to an age- and gender-matched control group (8.4 +/- 1.9 years, p = 0.45). RESULTS Maximal oxygen uptake in patients (48.6 +/- 7.1 mL O(2)/min/kg) was similar to normal controls (47.4 +/- 5.2 mL/min/kg, p > 0.25). The inclination of the treadmill at maximal exercise was significantly (p = 0.02) lower in patients (12.6 +/- 4.9%) versus controls (16.0 +/- 3.5%). During submaximal exercise, oxygen uptake (expressed as mL/min/kg or as a percent of maximal oxygen uptake) was significantly higher (p < 0.001) in patients compared to normal controls. CONCLUSION Children with exertional fatigue as compared to healthy controls, have a higher oxygen uptake for the same level of exercise and therefore perform at each level of exercise closer to their maximal exercise capacity. This may in part explain subjective complaints of poor exercise tolerance.
Collapse
Affiliation(s)
- T Reybrouck
- Department of Cardiovascular Rehabilitation, University Hospital Gasthuisberg, University of Leuven, Belgium.
| | | | | | | |
Collapse
|
15
|
Davidson RM, McNeer JF, Logan L, Higginbotham MB, Anderson J, Blackshear J, Chu A, Hettleman B, McGrew F, Meesse R, O'Connor C, Schneider R, Wagner GS. A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. Am Heart J 2006; 151:451-6. [PMID: 16442913 DOI: 10.1016/j.ahj.2005.04.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2004] [Accepted: 04/08/2005] [Indexed: 11/15/2022]
Abstract
BACKGROUND The purpose of this report is to present a model of physicians in full-time clinical practice participating as investigators in multicenter clinical trials, sponsored by a pharmaceutical or medical device company. METHODS This gas-exchange substudy was conducted as a pilot study to establish the feasibility of the 10-member EXERcise testing group of the Duke University Cooperative Cardiovascular Society (EXERDUCCS) consortium to perform a complex multicenter trial using cardiopulmonary exercise testing. An active interchange of information was established involving the principal investigator for the substudy, a dedicated full-time project coordinator, a medical director of the overall EXERDUCCS network site, the project coordinator for the sponsor, and all the participating EXERDUCCS investigators and coordinators. RESULTS The sponsor set as a goal of enrollment of 6 subjects per site, and 8 of the 10 sites met this goal. As a result of the successful enrollment and completion of the study and substudy by the EXERDUCCS sites, the sponsor subsequently increased the payment stipends to the sites to compensate for the extra work and expense incurred. CONCLUSIONS This cooperative experience accomplished several goals: (1) it allowed a complex clinical trial to be successfully completed in a time frame which would not have been possible using only single unconnected sites; (2) it educated the physician-investigators (and their personnel) in exercise cardiopulmonary; and (3) it prepared the sites for future clinical trials involving this methodology.
Collapse
|
16
|
Larsen AI, Lindal S, Aukrust P, Toft I, Aarsland T, Dickstein K. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. Int J Cardiol 2002; 83:25-32. [PMID: 11959380 DOI: 10.1016/s0167-5273(02)00014-1] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND In patients with congestive heart failure (CHF) there is a shift from aerobic type I muscle fibres to less aerobic type II fibres. Exercise training has been shown to have beneficial effects on exercise performance, peripheral pathology and the neurohumoral profile in stable patients with CHF. This study evaluated the effect of a 3 month exercise training program on skeletal muscle characteristics and the correlation of these to cytokines and exercise capacity in CHF patients. METHODS Skeletal muscle biopsies for enzyme-histochemical analysis were performed in 15 CHF patients in New York Heart Association classes II-III, with a mean ejection fraction of 33+/-5% before and after a 12 week training period. The patients were trained for 30 min, five times a week at 80% of the peak heart rate achieved at baseline ergometer cycle test. Fifteen healthy men were used as controls. Plasma samples were examined by enzyme immunoassays for levels of pro-inflammatory cytokines. RESULTS (a) At baseline we found muscle atrophy in five of the patients. The percent area of type I fibres (40.7+/-12.0 vs. 56.4+/-11.0%, P<0.05) and the thickness of type IIA (56.10+/-7.8 vs. 71.6+/-11.9 microm, P<0.001) and B-fibres (49.0+/-8.9 vs. 63.9+/-10.6 microm, P<0.001) were reduced, whereas the percent area of type IIA fibres (52.1+/-13.3 vs. 36.4+/-9.9%, P<0.05) was increased in heart failure patients compared to healthy controls. There was a modest correlation between fibre thickness and the level of interleukin 6 (r=-0.657, P=0.008). (b) After exercise training there was a reduction in muscle area examined by light-microscopy, measured as a percentage of field (-2.7, P=0.003) with an concomitant increase in interstitium. This reduction correlated to the increase in the 6-min walk test (r=-0.558, P=0.031). The thickness of type IIB fibres increased (+5.6 microm, P=0.068) and the area of type I fibres decreased (-6.1%, P=0.062). CONCLUSIONS Patients with CHF have a relatively increased area of type IIA fibres and a relatively decreased area of type I fibres compared to healthy individuals. The thickness of type IIA and type IIB fibres is decreased compared to normal individuals. A modest negative correlation between the level of interleukin 6 and fibre thickness at baseline, suggests that inflammatory cytokines may be involved in the pathogenesis of the CHF related myopathy. A significant correlation between the reduction of muscle area, with increased interstitum, and the increase in the 6-min walk test may indicate that the improvement is due to increased capillary density permitting better flow reserve to exercising muscles.
Collapse
Affiliation(s)
- Alf Inge Larsen
- Cardiology Division, Central Hospital in Rogaland, P.O. Box 8100, N4001 Stavanger, Norway.
| | | | | | | | | | | |
Collapse
|
17
|
Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000; 102:728-35. [PMID: 10942739 DOI: 10.1161/01.cir.102.7.728] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Antiplatelet therapy is the mainstay of the treatment and secondary prevention of cardiovascular and cerebrovascular ischemic events. We assessed the safety, tolerability, and pharmacodynamics of lotrafiban, an oral platelet glycoprotein IIb/IIIa inhibitor, as a secondary prevention strategy in patients with cerebrovascular or cardiovascular disease. METHODS AND RESULTS Overall, 451 patients with a recent cardiovascular or cerebrovascular acute ischemic event were randomized in a double-blind fashion to 1 of 5 dosing regimens for 12 weeks: placebo or 5, 20, 50, or 100 mg lotrafiban, both twice daily with 300 to 325 mg/d aspirin. The primary end point was the incidence and tolerability of major and minor bleeding during treatment. Secondary end points included inhibition of platelet aggregation and clinical events. The placebo and lotrafiban 5-mg groups had similarly low rates of minor and major bleeding, but the 100-mg arm was terminated early because of excess major bleeding. Protocol-defined thrombocytopenia (<100 000 platelets/microL) occurred in 5 lotrafiban-treated patients (1.4%, 95% CI 0.2% to 2.7%) and 1 placebo patient (1.1%, 95% CI 0% to 3.1%). Three lotrafiban-treated patients had a nadir platelet count <20 000/microL (0.9%, 95% CI 0% to 1.8%). Lotrafiban produced dose-dependent inhibition of platelet aggregation; 5 mg lotrafiban did not differ significantly from placebo, whereas 100 mg inhibited aggregation by nearly 100%. CONCLUSIONS -Lotrafiban provides dose-dependent platelet inhibition when administered to a range of patients with atherosclerosis. The level of platelet inhibition appears to correlate with bleeding risk and drug tolerability.
Collapse
Affiliation(s)
- R A Harrington
- Duke Clinical Research Institute, Durham, NC 27715, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|